Author

Oren Moscovitz

Max Planck Institute of Colloids and InterfacesORCID 0000-0002-6310-2579Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Felix GoerdeleriD· 2 shared Jost LühleiD· 2 shared Peter H. SeebergeriD· 2 shared Anika FreitagiD· 1 shared Carsten KamphuesiD· 1 shared Christian Martin SeitziD· 1 shared Christian RothiD· 1 shared Gustavo Marçal Schmidt Garcia MoreiraiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Felix GoerdelerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An Integrative Approach to Develop and Characterise Antibodies Against the Cancer Associated Antigen Sialyl Lewis A (CA 19-9)

Anika Freitag, Sana Khan Khilji, Ruslan Nedielkov, Shalini Murali Kumar, Michael Krummhaar, Janine Arndt, Gustavo Marçal Schmidt Garcia Moreira, Jost Lühle, Felix Goerdeler, Carsten Kamphues, María Andrea Mroginski, Christian Roth, Peter H. Seeberger, Heiko Michael Möller, Oren Moscovitz

This paper develops and characterizes novel monoclonal antibodies against sLeA, showing improved affinity and specificity compared to existing antibodies.

bioRxiv · Jun 15, 2025 · PreprintCancer Biology

Cysteine-Engineered CAR-T Cells to Counter Antigen Escape in B Cell Lymphoma

Jost Lühle, Simon Krost, Felix Goerdeler, Christian Martin Seitz, Peter H. Seeberger, Oren Moscovitz

This paper introduces cysteine-engineered CAR-T cells that target both conventional antigens and altered redox states in B cell lymphoma, reducing the risk of antigen escape.

bioRxiv · Apr 1, 2025 · PreprintCancer Biology